INVITED SPEAKERS

Associate-Professor Morton Burt
Southern Adelaide Diabetes and Endocrine Service

Associate-Professor Morton Burt is an Endocrinologist working within the Southern Adelaide Diabetes and Endocrine Service. He is also Editor for Endocrinology for the Internal Medicine Journal and a member of the Council of the Endocrine Society of Australia. After clinical training Associate-Professor Burt completed a PhD at the Garvan Institute of Medical Research, Sydney, investigating the effect of glucocorticoid excess on protein metabolism. His primary research interest currently is the effect of glucocorticoid excess on carbohydrate metabolism and cardiovascular risk. Associate-Professor Burt’s clinical interests are pituitary and genetic endocrine disease.

Mr Leo Fernon
Concord Hospital

Leo Turner has been the clinical nurse consultant of Andrology for almost 30 years originally at Royal Prince Alfred Hospital and then with the move to Concord Hospital. During this time he also managed the laboratory for 10 years. The move to Concord coincided with the building of the ANZAC research Institute in which the department is closely affiliated. Leo’s interests include the investigation and treatment for male hypogonadism, male fertility, sperm cryostorage for cancer and male hormonal contraception which he completed his master’s thesis on. The Department has a very strong research focus and Leo has been a co-investigator on many studies.

Professor David Handelsman
University of Sydney

David Handelsman is Professor of Reproductive Endocrinology and Andrology, founding Professor/Director of the ANZAC Research Institute, inaugural Head, Andrology Department, Concord Hospital and Associate Dean (Research Centres) at University of Sydney Medical School. After Endocrinology training and NHMRC & Welcome Trust postdoctoral fellowships, he become Australia’s first Professor of Andrology (1996), created the first hospital Andrology Department (1999) and established the ANZAC Research Institute (2000). The most widely cited author world-wide on “androgens” or “testosterone”, he has over 500 peer-reviewed papers which are cited >12,000 times (h index 58; Web of Science). He wrote an editorial for the New England Journal of Medicine (2013) and had work cited in a Time magazine cover story on testosterone use (2014). His research focuses on androgen physiology, pharmacology and toxicology most recently in genetic models of androgen action, steroid mass spectrometry, anti-doping science, and clinical and epidemiological androgen pharmacology.

Associate Professor Warrick Inder
University of Queensland

Dr Inder graduated from the University of Otago, NZ in 1988. He obtained his MD examining the effects of opioid peptides on ACTH secretion, before spending 2 years in the Neuroendocrine Unit of the Massachusetts General Hospital, Boston USA on a post-doctoral fellowship researching pituitary adenomas. He has worked as consultant Endocrinologist at Christchurch Hospital, NZ and St Vincent’s Hospital, Melbourne and is currently a senior staff specialist at Princess Alexandra Hospital, Brisbane and associate professor with the University of Queensland. He is the President-elect of the Endocrine Society of Australia and chair of the Specialist Advisory Committee in Endocrinology for the Royal Australasian College of Physicians. His major clinical and research interests are pituitary and adrenal disease.

Dr Stephen Santoreneos
Women’s and Children’s Hospital, Adelaide

Throughout my University years I was always fascinated and somewhat intimidated by neurology. A 5th year elective in Neurosurgery under Mr. Ahmed Hanieh showed me a world of challenges lying ahead in what I considered the most interesting field of medicine. The complexity of the nervous system, its intriguing anatomy and the fascinating technical developments in this field were some of the attractions. Internship and basic residency served only to reinforce this just as the rich South Australian history of pioneering work in this field did.
**Professor David Torpy**  
*Royal Adelaide Hospital*

David Torpy is a Consultant Endocrinologist at the Royal Adelaide Hospital. His research interests predominantly involve studies of the hypothalamic-pituitary-adrenal axis and stress. Recent specific areas have included corticosteroid-binding globulin (CBG) genetic variants and their effect on the stress response, immune-HPA interactions involving CBG in inflammatory states, adrenal function in septic shock, maternal cortisolaemia in complicated pregnancies, inherited forms of adrenal dysfunction causing Cushing’s, adrenocortical carcinoma, opioids and adrenal function, the stress axis in hypoglycaemia unawareness, and cortisone dosing and well-being in Addison’s disease.

**Dr Michael Tuttle**  
*Memorial Sloan Kettering Cancer Center, New York, USA*

Dr R Michael Tuttle, an Endocrinologist and Professor of Medicine at Memorial Sloan Kettering Cancer Center in New York, designed and validated the first real time risk assessment model for thyroid cancer management in which individual risk estimates are modified over time as a function of response to initial therapy. In addition, his clinical studies have helped to define the role of recombinant human TSH as an adjuvant for radioactive iodine therapy in both low risk and high risk patients and in the setting of radioactive iodine avid distant metastases. His research continues to center on important management aspects of thyroid cancer including efforts to better define of risk of recurrence, risk of death, and the potential role for observation in low risk thyroid cancer. His clinical practice is entirely devoted to patients with thyroid cancer with a particular emphasis on cases with aggressive disease and complicated management issues.